BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8270975)

  • 21. High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a phase I study.
    Saez RA; Slease RB; Strnad C; Selby GB; Confer DL; Epstein RB
    Bone Marrow Transplant; 1995 Oct; 16(4):507-14. PubMed ID: 8528165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.
    Rose PG; Smrekar M; Haba P; Visser C; Beeler JF
    Gynecol Oncol; 2005 Dec; 99(3):714-9. PubMed ID: 16112177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
    Bezwoda WR; Seymour L; Dansey RD
    J Clin Oncol; 1995 Oct; 13(10):2483-9. PubMed ID: 7595697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.
    Lotz JP; Machover D; Malassagne B; Hingh B; Donsimoni R; Gumus Y; Gerota J; Lam Y; Tulliez M; Marsiglia H
    J Clin Oncol; 1991 Oct; 9(10):1860-70. PubMed ID: 1919636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
    Fields KK; Elfenbein GJ; Lazarus HM; Cooper BW; Perkins JB; Creger RJ; Ballester OF; Hiemenz JH; Janssen WE; Zorsky PE
    J Clin Oncol; 1995 Feb; 13(2):323-32. PubMed ID: 7844593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Kurbacher CM; Bruckner HW; Cree IA; Kurbacher JA; Wilhelm L; Pöch G; Indefrei D; Mallmann P; Andreotti PE
    Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
    Antman K; Ayash L; Elias A; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper LE; Frei E
    J Natl Cancer Inst Monogr; 1994; (16):91-4. PubMed ID: 7528031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
    Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.
    Antman K; Ayash L; Elias A; Wheeler C; Hunt M; Eder JP; Teicher BA; Critchlow J; Bibbo J; Schnipper LE
    J Clin Oncol; 1992 Jan; 10(1):102-10. PubMed ID: 1727912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis of relative factors of bone marrow suppression after chemotherapy with carboplatin and paclitaxel on the patients with ovarian cancer].
    Ding D; Kong WM
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):188-92. PubMed ID: 21575452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.
    Eder JP; Elias A; Shea TC; Schryber SM; Teicher BA; Hunt M; Burke J; Siegel R; Schnipper LE; Frei E
    J Clin Oncol; 1990 Jul; 8(7):1239-45. PubMed ID: 2162912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation.
    Neidhart JA; Kohler W; Stidley C; Mangalik A; Plauche A; Anderson T; Quenzer RW; Rinehart JJ
    J Clin Oncol; 1990 Oct; 8(10):1728-38. PubMed ID: 2213108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
    Wallerstein R; Spitzer G; Dunphy F; Huan S; Hortobagyi G; Yau J; Buzdar A; Holmes F; Theriault R; Ewer M
    J Clin Oncol; 1990 Nov; 8(11):1782-8. PubMed ID: 2121909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors.
    Broun ER; Nichols CR; Mandanas R; Salzman D; Turns M; Hromas R; Cornetta K; Einhorn LH
    Bone Marrow Transplant; 1995 Sep; 16(3):353-8. PubMed ID: 8535306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
    Patrone F; Ballestrero A; Ferrando F; Brema F; Moraglio L; Valbonesi M; Basta P; Ghio R; Gobbi M; Sessarego M
    J Clin Oncol; 1995 Apr; 13(4):840-6. PubMed ID: 7707109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.